Clinical trials: Tocilizumab
Epilepsy
Possible Immuno-Modulatory Effect of Tocilizumab in Patients With Refractory Status Epilepticus.
Recently, the pathogenesis of epilepsy is immuno-modulatory and neuro-inflammatory which is commonly activated in epileptogenic brain regions in humans and is clearly involved in animal models of epilepsy.
- Trial name
- NCT05346666
- Testing
- Tocilizumab Prefilled Syringe [Actemra]. propofole, phenobarbital, midazolam
- Where
- Egypt
- Volunteers
- 50 people
- Sponsor
- Damanhour University
COVID-19
Tocilizumab to Prevent Clinical Decompensation in Hospitalized, Non-critically Ill Patients With COVID-19 Pneumonitis
Coronavirus disease-2019 (COVID-19) has a quoted inpatient mortality as high as 25%. This high mortality may be driven by hyperinflammation resembling cytokine release syndrome (CRS), offering the hope that therapies targeting…
- Trial name
- COVIDOSE (NCT04331795)
- Testing
- Tocilizumab
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- University of Chicago
Rheumatoid Arthritis of Knee
The Comparative Study of Intra-articular Injection of Tocilizumab and Compound Betamethasone
Aim: Comparing the efficacy and safety of intra-articular injection of tocilizumab and compound betamethasone. Study design: A randomized, single-blind, parallel controlled and one center trial design. Sample size: 60 cases.
- Trial name
- NCT03215407
- Testing
- Intra-articular Tocilizumab, Intra-articular Compound Betamethasone
- Volunteers
- 60 people
- Sponsor
- Chinese PLA General Hospital
Rheumatoid Arthritis
An Observational Study of Glucocorticoid Use in Patients With Rheumatoid Arthritis on Treatment With RoActemra/Actemra (Tocilizumab)
This observational study will evaluate the glucocorticoid sparing effect after 12 months of treatment with RoActemra/Actemra (tocilizumab) in patients with rheumatoid arthritis.
- Trial name
- NCT01392001
- Where
- 116 sites in France
- Volunteers
- 322 people
- Sponsor
- Hoffmann-La Roche
Rheumatoid Arthritis
ARMONIA: An Observational Study of Biologic Drugs in Monotherapy or Combination With DMARDs in Italian Clinical Practice and the Efficacy and Safety of RoActemra/Actemra (Tocilizumab) Monotherapy in Patients With Rheumatoid Arthritis
This is a multicenter observational study in patients with rheumatoid arthritis in routine clinical practice in Italy. In the retrospective Part 1 of the study, clinical and demographic factors associated with the use of a…
- Trial name
- NCT01791205
- Where
- 28 sites in Italy
- Volunteers
- 304 people
- Sponsor
- Hoffmann-La Roche
SARS-CoV-2 Infection
Tocilizumab in the Treatment of Coronavirus Induced Disease (COVID-19)
The mortality rate of the disease caused by the corona virus induced disease (COVID-19) has been estimated to be 3.7% (WHO), which is more than 10-fold higher than the mortality of influenza.
- Trial name
- CORON-ACT (NCT04335071)
- Testing
- Tocilizumab (TCZ)
- Where
- 4 sites in Switzerland
- Volunteers
- 5 people
- Sponsor
- Insel Gruppe AG, University Hospital Bern
Covid19, Pneumonia
Comparative Therapeutic Efficacy and Safety of Different Antiviral and Anti Inflammatory Drugs in COVID-19 Patients.
Comparison outcomes of a large cohort of moderate and severe COVID-19 patients received different Antiviral and Anti Inflammatory Drugs.
- Trial name
- NCT04779047
- Testing
- Remdesivir, Hydroxychloroquine, Tocilizumab
- Where
- Egypt
- Volunteers
- 150 people
- Sponsor
- October 6 University
Behcet Syndrome
Tocilizumab for the Treatment of Behcet's Syndrome
This is a double-blind placebo controlled study targeting individuals with active Behcet's Syndrome who have oral ulcers and are resistant (have not responded after 4 weeks) to conventional treatments.
- Trial name
- NCT01693653
- Testing
- Tocilizumab
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- NYU Langone Health
COVID-19
Clinical Trial of the Use of Tocilizumab for Treatment of SARS-CoV-2 Infection (COVID-19)
COVID-19 is a respiratory disease caused by the new coronavirus (SARS-CoV-2) and causes considerable morbidity and mortality. Currently, there is no vaccine or therapeutic agent to prevent and treat a SARS-CoV-2 infection.
- Trial name
- TOCOVID (NCT04332094)
- Testing
- Tocilizumab, Hydroxychloroquine, Azithromycin
- Where
- 7 sites in Spain
- Volunteers
- 276 people
- Sponsor
- Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
Rheumatoid Arthritis
An Observational Study of Dosage Patterns in Routine Clinical Practice in Patients With Rheumatoid Arthritis (ACT-LIFE)
This observational study will evaluate the dosage patterns, safety and efficacy of RoActemra/Actemra (tocilizumab) in clinical practice in patients with moderate to severe rheumatoid arthritis who have not responded or are…
- Trial name
- NCT01338545
- Where
- 48 sites in United States, Spain
- Volunteers
- 400 people
- Sponsor
- Hoffmann-La Roche
Rheumatoid Arthritis
A Study of the Effect of Tocilizumab on Markers of Atherogenic Risk in Patients With Moderate to Severe Rheumatoid Arthritis
This 2 arm study will investigate the effects of tocilizumab on lipids, arterial stiffness, and markers of atherogenic risk in patients with moderate to severe active rheumatoid arthritis.
- Trial name
- NCT00535782
- Testing
- Tocilizumab, Methotrexate
- Where
- 40 sites in United States, Canada and 2 more
- Volunteers
- 132 people
- Sponsor
- Hoffmann-La Roche
Rheumatoid Arthritis
A Non-interventional Study of RoActemra/Actemra (Tocilizumab) in Patients With Rheumatoid Arthritis
This multi-center, observational study will evaluate the clinical practice patterns, efficacy and safety of RoActemra/Actemra (tocilizumab) in participants with moderate to severe rheumatoid arthritis.
- Trial name
- NCT01562327
- Testing
- Tocilizumab
- Where
- 7 sites in Argentina
- Volunteers
- 50 people
- Sponsor
- Hoffmann-La Roche
Rheumatoid Arthritis
A Study Of Tocilizumab in Patients With Moderate to Severe Active Rheumatoid Arthritis Who Have an Inadequate Response to or Are Unable to Tolerate Biologic and Non-Biologic Disease-modifying Antirheumatic Drugs (DMARDs)
This 3 arm randomized open label study will evaluate the safety, tolerability and efficacy of tocilizumab in patients with moderate to severe active rheumatoid arthritis, who have had inadequate response to or are unable to…
- Trial name
- NCT00891020
- Testing
- tocilizumab [RoActemra/Actemra], Nonbiologic DMARDs of investigator's choice
- Where
- 227 sites in United States
- Volunteers
- 886 people
- Sponsor
- Hoffmann-La Roche
Polymyalgia Rheumatica
A Study to Evaluate the Efficacy of Tocilizumab as a Remission-Induction and Glucocorticoid-Sparing Regimen in Subjects With New-Onset Polymyalgia Rheumatica (PMR- SPARE)
The purpose of this study is to assess the efficacy of a tocilizumab-based regimen compared with placebo on top of rapidly tapered glucocorticoid treatment in a double- blind, controlled fashion, focussing on glucocorticoid-free…
- Trial name
- NCT03263715
- Testing
- Tocilizumab Prefilled Syringe [Actemra], Glucocorticoids
- Where
- 3 sites in Austria
- Volunteers
- 39 people
- Sponsor
- Medical University of Vienna
Rheumatoid Arthritis
A Study of the Effects of RoActemra/Actemra on Vaccination in Patients With Rheumatoid Arthritis on Background Methotrexate (VISARA)
This randomized, parallel-group, open-label study will evaluate the effect of Actemra (tocilizumab) on vaccination in patients with active rheumatoid arthritis who have an inadequate response to methotrexate and who have had an…
- Trial name
- NCT01163747
- Testing
- tocilizumab, methotrexate, 23-Valent Pneumococcal Polysaccharide Vaccine
- Where
- 47 sites in United States
- Volunteers
- 91 people
- Sponsor
- Genentech, Inc.
Rheumatoid Arthritis
A Long-Term Extension Study of WA19926 on the Safety of Tocilizumab (RoActemra/Actemra) in Participants With Early Moderate to Severe Rheumatoid Arthritis
This open-label, single arm, multicenter long-term extension study will evaluate the safety and efficacy of tocilizumab (RoActemra/Actemra) in participants with moderate to severe rheumatoid arthritis who have completed the…
- Trial name
- NCT01655381
- Testing
- Tocilizumab
- Where
- 6 sites in France
- Volunteers
- 15 people
- Sponsor
- Hoffmann-La Roche
Calciphylaxis
Anti-Interleukin-6 (IL6) in Calciphylaxis
Calciphylaxis is a rare but incredibly dangerous condition that causes small blood vessels in the skin to become blocked by calcium buildup and blood clots. This leads to painful skin sores (necrosis) that do not heal easily.
- Trial name
- NCT07708038
- Testing
- Tocilizumab
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Boston Medical Center
Healthy Subjects
A Study to Compare the Pharmacokinetics and Safety of CT-P47 and RoActemra in Healthy Subjects
A study to Compare the Pharmacokinetics and Safety of CT-P47 and RoActemra in Healthy Subjects
- Trial name
- NCT05188378
- Testing
- CT-P47, EU-approved RoActemra,
- Where
- South Korea
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Celltrion
COVID-19, Cytomegalovirus (CMV), Tocilizumab, Anakinra, Mortality
The Relationship Between CMV* Reactivation and Anti-cytokine Treatment in Critical COVID-19 Patients
The risk of secondary infection is high in critical patients hospitalized with the diagnosis of COVID-19. Immunosuppressive treatments are commonly used in critical COVID-19 patients, and immune dysfunction and CMV reactivation…
- Trial name
- Cytomegalovir (NCT05419206)
- Testing
- CMV DNA analysis
- Where
- Turkey (Türkiye)
- Volunteers
- 167 people
- Sponsor
- Ramazan Gozukucuk
Glucocorticosteroid Refractory Acute GVHD
Phase II Study of Tocilizumab for Patients With Glucocorticoid-refractory Acute GVHD After Allogeneic Hematopoetic Stem Cell Transplant (HSCT)
The purpose of this study is to determine if Tocilizumab is a safe and effective treatment for steroid-refractory acute graft versus host disease.
- Trial name
- NCT01757197
- Testing
- Toclizumab
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Weill Medical College of Cornell University